Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Mar 3;59(3):2100651.
doi: 10.1183/13993003.00651-2021. Print 2022 Mar.

In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study

Affiliations
Free article
Observational Study

In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study

Alexandre Descamps et al. Eur Respir J. .
Free article

Abstract

Objectives: The purpose of this study was to describe the clinical characteristics and in-hospital and post-discharge outcomes of respiratory syncytial virus (RSV) infection among adults hospitalised with influenza-like illness (ILI) and compared against patients admitted for influenza.

Methods: Adults hospitalised with ILI were prospectively included from five French university hospitals over two consecutive winter seasons (2017/2018 and 2018/2019). RSV and influenza virus were detected by multiplex reverse transcription PCR on nasopharyngeal swabs. RSV-positive patients were compared to RSV-negative and influenza-positive hospitalised patients. Poisson regression models were used to estimate the adjusted prevalence ratio (aPR) associated with in-hospital and post-discharge outcomes between RSV and influenza infections. The in-hospital outcome was a composite of the occurrence of at least one complication, length of stay ≥7 days, intensive care unit admission, use of mechanical ventilation and in-hospital death. Post-discharge outcome included 30- and 90-day all-cause mortality and 90-day readmission rates.

Results: Overall, 1428 hospitalised adults with ILI were included. RSV was detected in 8% (114 of 1428) and influenza virus in 31% (437 of 1428). Patients hospitalised with RSV were older than those with influenza (mean age 73.0 versus 68.8 years, p=0.015) with a higher frequency of chronic respiratory or cardiac disease (52% versus 39%, p=0.012, and 52% versus 41%, p=0.039, respectively) and longer hospitalisation duration (median stay 8 versus 6 days, p<0.001). Anti-influenza therapies were less prescribed among RSV patients than influenza patients (20% versus 66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1-2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8-1.6).

Conclusion: RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Lenzi has nothing to disclose. Conflict of interest: F. Galtier has nothing to disclose. Conflict of interest: F. Lainé has nothing to disclose. Conflict of interest: Z. Lesieur has nothing to disclose. Conflict of interest: P. Vanhems reports grants from Pfizer, Sanofi, Anios, MSD and Astellas, outside the submitted work. Conflict of interest: S. Amour has nothing to disclose. Conflict of interest: A-S. L'Honneur has nothing to disclose. Conflict of interest: N. Fidouh has nothing to disclose. Conflict of interest: V. Foulongne has nothing to disclose. Conflict of interest: G. Lagathu has nothing to disclose. Conflict of interest: X. Duval has nothing to disclose. Conflict of interest: C. Merle has nothing to disclose. Conflict of interest: B. Lina has nothing to disclose. Conflict of interest: F. Carrat has nothing to disclose. Conflict of interest: O. Launay is principal investigator for clinical trials sponsored by Janssen, GSK, Pfizer, Sanofi Pasteur and MSD, outside the submitted work. Conflict of interest: P. Loubet reports personal fees from Pfizer and non-financial support from Sanofi Pasteur, outside the submitted work. Conflict of interest: A. Descamps has nothing to disclose.

Publication types